
Conference Coverage
about 1 month ago
2026 Conference Insights: ASCPabout 1 month ago
2026 Conference Insights: APAabout 1 month ago
2026 Conference Insights: SIRSLatest Content

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness

How Do Cannabis Edibles Affect Driving? New Research Insights

Ethics and AI Use in Medical Practice: American College of Physicians Releases Position Statement

New Research Explores the Genetic Roots of Hair-Pulling and Skin-Picking, Connection to OCD

International Overdose Awareness Day Marks 25th Year as US Overdose Deaths Decline Yet Remain High

Shorts










Digital Edition
Podcasts
Continuing Medical Education
All News

Much of what we call "treatment-resistant" depression may be mismatched, not resistant. A psychiatrist makes the case for trading the failed-drug tally for a difficult-to-treat framework clinicians can act on Monday morning.

BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.

Check out our pipeline updates from August!

Axsome launches SUMMIT phase 3 testing AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

Review news in psychiatry from the last week.

Livestreamed insanity trials reshape public opinion, exposing myths, bias, and psychiatry’s educator role, in cases like the M’Naghten trial to the curent Clancy trial.

Drs Clark and Walton discuss ADHD in underrecognized groups, along with treatment and lifestyle options.

Meta faces an $18B teen-safety settlement, adding time limits, night and school modes, parental controls, and tighter age checks across Instagram and Facebook.

Experts weigh benzodiazepine benefits, dependence myths, and safer prescribing in older adults, including what evidence really says about Alzheimer risk.

New donanemab dosing cuts ARIA-E risk, speeds MRI monitoring, and shows durable 3-year benefits with lasting biomarker gains in early Alzheimer’s.

High-profile infanticide trial fuels debate over postpartum illness, malpractice claims, and whether psychiatrists should be judged for patients’ crimes rather than care quality.

Plasma P-tau217 blood tests match amyloid PET for early Alzheimer pathology, offering scalable, noninvasive detection and forecasting cognitive decline risk years ahead.

A psychiatrist shares how mindfulness, vulnerability, and shared presence strengthen therapy, reduce burnout, and reshape modern psychiatric care.

Impaired self-awareness is a frequent and impactful consequence of traumatic brain injury (TBI), occurring in as many as 40% to 80% of individuals with moderate-to-severe TBI. Deficits in self-awareness can negatively impact goal setting, treatment compliance, and motivation for therapy. Addressing this impairment through targeted interventions can improve rehabilitation outcomes, psychosocial adjustment, and community participation.











































